POLBF (Poolbeg Pharma) Other Operating Expense: $-0.57 Mil (TTM As of Dec. 2025)


What is Poolbeg Pharma Other Operating Expense?

Poolbeg Pharma POLBF Other Operating Expense is $-0.57 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Other Operating Expense for the six months ended in Dec. 2025 was $-0.29 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.57 Mil.

Poolbeg Pharma's quarterly Other Operating Expense increased from Dec. 2024 ($-0.31 Mil) to Jun. 2025 ($-0.28 Mil) but then declined from Jun. 2025 ($-0.28 Mil) to Dec. 2025 ($-0.29 Mil).

Poolbeg Pharma's annual Other Operating Expense declined from Dec. 2023 ($-0.46 Mil) to Dec. 2024 ($-0.67 Mil) but then increased from Dec. 2024 ($-0.67 Mil) to Dec. 2025 ($-0.56 Mil).

Poolbeg Pharma Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Other Operating Expense Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
-0.15 -0.34 -0.46 -0.67 -0.56

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only -0.24 -0.36 -0.31 -0.28 -0.29

Poolbeg Pharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.57 Mil mean?
Poolbeg Pharma (POLBF) has a Other Operating Expense of $-0.57 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Other Operating Expense too high?
Poolbeg Pharma's current Other Operating Expense is $-0.57 Mil.
How does Poolbeg Pharma's Other Operating Expense compare to VRTX and REGN?
Poolbeg Pharma's Other Operating Expense of $-0.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Other Operating Expense is $-0.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Other Operating Expense of $-0.57 Mil. The current Other Operating Expense is $-0.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Other Operating Expense is $-0.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.